Result for quarter ended 31-12-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 2.7 pts more than its Trading - Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Evexia Lifecare Limited reported its Q3 FY26 results with standalone revenue from operations of Rs. 2,459.92 lakhs, up about 14% from Rs. 2,157.97 lakhs in Q3 FY25. Standalone profit after tax jumped to Rs. 40.73 lakhs from Rs. 19.23 lakhs, more than doubling year-on-year. For the nine-month period, standalone revenue rose modestly to Rs. 7,028.54 lakhs (from Rs. 6,870.76 lakhs) while PAT grew to Rs. 131.58 lakhs (from Rs. 117.80 lakhs). On a consolidated basis, Q3 revenue was Rs. 2,524.38 lakhs and PAT was Rs. 29.19 lakhs, both showing strong growth versus the prior year quarter. The auditor (Tejas K. Soni and Company) issued an unmodified limited review conclusion but flagged an Emphasis of Matter noting that subsidiary results included in the consolidation are based on non-audited financial statements.
Sharp year-on-year PAT growth in Q3 is a positive signal for shareholders, though the absolute earnings remain small relative to the company's large equity base (EPS of Rs. 0.002). The Emphasis of Matter on unaudited subsidiary financials is worth monitoring but the auditor did not modify its conclusion.